167 related articles for article (PubMed ID: 34467658)
1. Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients.
Valencia Deray KG; Hosek KE; Chilukuri D; Dunson JR; Spielberg DR; Swartz SJ; Spinner JA; Leung DH; Moulton EA; Munoz FM; Demmler-Harrison GJ; Bocchini CE
Am J Transplant; 2022 Jan; 22(1):187-198. PubMed ID: 34467658
[TBL] [Abstract][Full Text] [Related]
2. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.
Liverman R; Serluco A; Nance G; George R; Rodriguez DS; Deshpande S; Mao C; Garro R; Yildirim I
Pediatr Transplant; 2023 Jun; 27(4):e14493. PubMed ID: 36945819
[TBL] [Abstract][Full Text] [Related]
3. Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients.
Schaenman J; Phonphok K; Spanuchart I; Duong T; Sievers TM; Lum E; Reed EF; Bunnapradist S
Transpl Infect Dis; 2021 Feb; 23(1):e13457. PubMed ID: 32892447
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.
Paulsen G; Cumagun P; Mixon E; Fowler K; Feig D; Shimamura M
Pediatr Transplant; 2019 May; 23(3):e13382. PubMed ID: 30786115
[TBL] [Abstract][Full Text] [Related]
5. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
[TBL] [Abstract][Full Text] [Related]
6. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
J Clin Virol; 2015 Oct; 71():73-5. PubMed ID: 26318605
[TBL] [Abstract][Full Text] [Related]
7. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
Perrottet N; Manuel O; Lamoth F; Venetz JP; Sahli R; Decosterd LA; Buclin T; Pascual M; Meylan P
BMC Infect Dis; 2010 Jan; 10():2. PubMed ID: 20053269
[TBL] [Abstract][Full Text] [Related]
8. Impact of standardized protocols for cytomegalovirus disease prevention in pediatric solid organ transplant recipients.
Ganapathi L; Blumenthal J; Alawdah L; Lewis L; Gilarde J; Jones S; Milliren C; Kim HB; Sharma TS
Pediatr Transplant; 2019 Nov; 23(7):e13568. PubMed ID: 31515909
[TBL] [Abstract][Full Text] [Related]
9. CMV infection and management among pediatric solid organ transplant recipients.
Downes KJ; Sharova A; Boge CLK; Vader D; Mitrou M; Hayes M; Galetaki DM; Gianchetti L; Vella LA; Li Y
Pediatr Transplant; 2022 May; 26(3):e14220. PubMed ID: 34994041
[TBL] [Abstract][Full Text] [Related]
10. Body surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients.
Demirhan S; Munoz FM; Valencia Deray KG; Bocchini CE; Danziger-Isakov L; Blum S; Sharma TS; Sherman G; Boguniewicz J; Bacon S; Ardura MI; Maron GM; Ferrolino J; Foca M; Herold BC
Am J Transplant; 2023 Dec; 23(12):1961-1971. PubMed ID: 37499799
[TBL] [Abstract][Full Text] [Related]
11. Early versus delayed initiation of cytomegalovirus prophylaxis after liver transplant.
Magid M; Byrns J; Gommer J; Yang Z; Lee HJ; Harris M
Pharmacotherapy; 2022 Aug; 42(8):634-640. PubMed ID: 35748517
[TBL] [Abstract][Full Text] [Related]
12. Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir.
Bedel AN; Hemmelgarn TS; Kohli R
Liver Transpl; 2012 Mar; 18(3):347-54. PubMed ID: 22139888
[TBL] [Abstract][Full Text] [Related]
13. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
14. GCV/VCVG prophylaxis against CMV DNAemia in pediatric renal transplant patients: A systematic review and meta-analysis.
Chatani B; Glaberson W; Nemeth Z; Tamariz L; Gonzalez IA
Pediatr Transplant; 2019 Sep; 23(6):e13514. PubMed ID: 31210393
[TBL] [Abstract][Full Text] [Related]
15. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
[TBL] [Abstract][Full Text] [Related]
16. Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients.
Valencia Deray KG; Danziger-Isakov LA; Downes KJ
J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S14-S21. PubMed ID: 38417084
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis.
Das BB; Prusty BK; Niu J; Sue PK
Pediatr Transplant; 2020 Dec; 24(8):e13750. PubMed ID: 32573886
[TBL] [Abstract][Full Text] [Related]
18. Healthcare disparity and its associations with cytomegalovirus disease in pediatric liver transplant recipients in South Africa.
Walabh P; Moore DP; Paget G; Meyer A; Moshesh PNM; Walabh P; Palweni ST; Hajinicolaou C
Transpl Infect Dis; 2022 Dec; 24(6):e13917. PubMed ID: 35870126
[TBL] [Abstract][Full Text] [Related]
19. Low-Dose Valganciclovir Prophylaxis Is Safe and Cost-Saving in CMV-Seropositive Kidney Transplant Recipients.
Shi Y; Lerner AH; Rogers R; Vieira K; Merhi B; Mecadon K; Osband AJ; Bayliss G; Gohh R; Morrissey P; Farmakiotis D
Prog Transplant; 2021 Dec; 31(4):368-376. PubMed ID: 34839729
[No Abstract] [Full Text] [Related]
20. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
